Skip to main content
. Author manuscript; available in PMC: 2024 Sep 26.
Published in final edited form as: J Infect. 2022 Mar 1;84(5):658–667. doi: 10.1016/j.jinf.2022.02.032

Fig. 2.

Fig. 2

Antibody responses against recombinant PorA (rPorA, P1.7,16). Groups of 4 to 8 BALB/c mice were immunized with a single dose of 109 infectious units (IU) of Ad-vectors and individual serum antibodies against 44/76-SL whole cells measured over time (A). BALB/c and NIH mice (N = 5) were immunized with 108 IU (Low) or 109 IU (high) of Ad-P1.7,16 and individual serum antibodies measured 2 weeks post vaccination (B). Comparison of antibody responses induced by Ad-P1.7,16 versus an OMV vaccine (C and D). Individual serum antibody endpoint titres were detected against rPorA P1.7,16 in groups of 4 to 8 NIH mice after a single dose of (109 IU) of Ad-P1.7,16 or 2 doses of 2.5 μg of OMV (44/76-FetAon PorAon) for up to 14 weeks (C). Individual serum antibody titers against 44/76-SL whole cells 2 weeks post vaccination of BALB/c and NIH mice (N = 5) with 108 IU (Low) or 109 IU (high) Ad-P1.7,16 or 2.5 μg of OMV (44/76-FetAon PorAon) (D). In panel C, the response against recombinant PorA protein is shown: A single dose of Ad PorA induces higher antibody titers than OMVs against PorA. In panel D, the response is measured against whole cells, containing other antigens than PorA, several also present in the OMVs. Mean serum individual values with SDs over time (A and C) or individual values at 2 weeks (B and D) are displayed. Dashed lines indicate negative cut-off values (titres obtained with sera from naïve mice). ANOVA was performed with Bonferroni multiple comparisons, ∗ P < .05, ∗∗ P < .01 and ∗∗∗∗ P < .0001 respectively.